Chronic Hepatitis B Virus Pipeline Insight
DelveInsight’s, “Chronic Hepatitis B Virus - Pipeline Insight, 2021,” report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Chronic Hepatitis B Virus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Chronic Hepatitis B Virus Understanding
Chronic Hepatitis B Virus: Overview
Chronic Hepatitis B Virus is a global public health threat that causes considerable liver-related morbidity and mortality. It is acquired at birth or later via person-to-person transmission. Vaccination effectively prevents infection and chronic hepatitis B virus carriage. In chronically infected patients, an elevated serum hepatitis B virus DNA concentration is the main risk factor for disease progression, although there are other clinical and viral parameters that influence disease outcomes. In addition to liver biochemistry, virological markers, and abdominal ultrasonography, non-invasive assessment of liver fibrosis is emerging as an important assessment modality. Long-term nucleos(t)ide-analogue therapy is safe and well tolerated, achieves potent viral suppression, and reduces the incidence of liver-related complications. However, a need to optimise management remains. Promising novel therapies are at the developmental stage.
"Chronic Hepatitis B Virus - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Hepatitis B Virus pipeline landscape is provided which includes the disease overview and Chronic Hepatitis B Virus treatment guidelines. The assessment part of the report embraces, in depth Chronic Hepatitis B Virus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Hepatitis B Virus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Hepatitis B Virus R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Hepatitis B Virus.
Chronic Hepatitis B Virus Emerging Drugs Chapters
This segment of the Chronic Hepatitis B Virus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Hepatitis B Virus Emerging Drugs
AB-729 (GalNAc-RNAi): Arbutus Biopharma
AB-729 is a subcutaneously-delivered RNAi therapeutic targeted to hepatocytes that inhibits viral replication and reduces all HBV antigens using our novel covalently conjugated GalNAc delivery technology. Currently, it is in Phase II stage of development to treat Chronic Hepatitis B Virus.
VIR-2218: Vir Biotechnology
VIR-2218, an HBV-targeting siRNA, is designed to inhibit the production of all HBV proteins, including hepatitis B virus surface antigen (HBsAg), which in turn is hypothesized to remove the inhibition of T cell activity directed against HBV. We believe that achieving a functional cure for many HBV patients may be enabled by using VIR-2218 in combination with other agents. Currently, it is in Phase II stage of development to treat Chronic Hepatitis B Virus.
Further product details are provided in the report……..
Chronic Hepatitis B Virus: Therapeutic Assessment
This segment of the report provides insights about the different Chronic Hepatitis B Virus drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chronic Hepatitis B Virus
There are approx. 45+ key companies which are developing the therapies for Chronic Hepatitis B Virus. The companies which have their Chronic Hepatitis B Virus drug candidates in the most advanced stage, i.e. phase II include, Vir Biotechnology.
DelveInsight’s report covers around 45+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Chronic Hepatitis B Virus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Chronic Hepatitis B Virus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Hepatitis B Virus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Hepatitis B Virus drugs.
Chronic Hepatitis B Virus Report Insights
- Chronic Hepatitis B Virus Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Chronic Hepatitis B Virus Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic Hepatitis B Virus drugs?
- How many Chronic Hepatitis B Virus drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Hepatitis B Virus?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Hepatitis B Virus therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic Hepatitis B Virus and their status?
- What are the key designations that have been granted to the emerging drugs?